Compare FSI & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | NSRX |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 52.5M |
| IPO Year | 1999 | 2025 |
| Metric | FSI | NSRX |
|---|---|---|
| Price | $5.53 | $5.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 56.9K | 4.6K |
| Earning Date | 11-14-2025 | 03-20-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $38,563,427.00 | N/A |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $53.12 | N/A |
| P/E Ratio | $39.44 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $3.46 | $5.42 |
| 52 Week High | $11.48 | $9.99 |
| Indicator | FSI | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.32 | 41.99 |
| Support Level | $5.65 | $5.42 |
| Resistance Level | $6.02 | $6.39 |
| Average True Range (ATR) | 0.29 | 0.32 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 6.43 | 21.35 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.